Second, owing to limited availability of covariate data, we were unable to examine the influence of concurrent lipid-lowering therapy on the estimates derived from the GRS for blood lipid traits and AAA risk. Third, our analyses used summary-level data as described elsewhere.16,48 Use of ...
Implementing an innovative lipid management technique using siRNA LDL-C lowering therapy: lessons learned in an NHS primary care practice with worked case examples. J Prim Care Community Health. 2023;14:21501319231172709. Article PubMed PubMed Central Google Scholar Deffert F, Vilela APO, Cobre ...
Vimalananda VG, Miller DR, Palnati M, Christiansen CL, Fincke BG (2011) Gender disparities in lipid-lowering therapy among veterans with diabetes. Womens Health Issues 21(4):S176–S181. https://doi.org/10.1016/j.whi.2011.04.009 Article PubMed Google Scholar Yu MK, Lyles CR, Bent-Sha...
Objective: Novel lipid-lowering therapies are being introduced. Few studies exist of the real-world effectiveness of adenosine-tri-phosphate citrate lyase inhibition with bempedoic acid. Methods: This study audited bempedoic acid therapy in 216 consecutive patients from three hospital centres - a ...
Material and methods Data on lipid-lowering therapy was collected prospectively, over an 8week period in August 2018, for all patients presenting with ACS. QRISK2 scores were calculated for patients admitted with ACS nave to statin therapy. Ethics approval was not required. Results Two-hundred ...
If the primary target LDLC is at goal, but non-HDLC or apoB is still high, attainment of all three targets will require intensified lipid-lowering therapy, lifestyle (re)inforcement, and/or additional TG-lowering drugs (e.g. fibrate or omega-3 fatty acids) [4]. Addition of PCSK9 ...
The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid-lowering therapy? Eye 2002; 16: 689–693. 43 Gordon B, Chang S, Kavanagh M, Berrocal M, Yannuzzi L, Robertson C et al. The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol 1991; ...
Patients with T1D elicited a more beneficial effect in lowering TC, LDL, and TG levels and in increasing HDL levels than their corresponding partners with T2D. In conclusion, long-term consumption of CM for patients with diabetes, especially those with T1D, could be a useful adjuvant therapy ...
profoundly decreased and exogenous phospholipid transfer protein induces apolipoprotein E secretion by primary human astrocytes in vitro.Understanding the relationship between lipid transfer proteins and lipoprotein metabolism is expected to be an important frontier in the search for a therapy for ...
After an average period of 10 months of initiation of alternative lipid lowering therapy;combination of low dose statin plus ezetimibe showed the largest reduction in serum total cholesterol and low-density lipoprotein (LDL) cholesterol levels. Conclusions: Pravastatin should be preferred in statin ...